Perspective Therapeutics (CATX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CATX Perspective Therapeutics

Watchlist

2.6100
-0.1000-3.69%

Close Feb 27 16:00 ET

2.7400
+0.1300+4.98%

Post 20:01 ET

176.40MMarket Cap-1.75P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Catalyst Watch: Nvidia Earnings, Amazon Product Event, PayPal Investor Day and Buffett's Letter
Seeking AlphaFeb 21 15:00 ET
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
GlobeNewswireFeb 21 07:00 ET
Home Healthcare Inflation Is Stubbornly High -- WSJ
WSJFeb 12 12:30 ET
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
GlobeNewswireFeb 5 07:00 ET
NYSE American Net Change Percentage Gainers & Losers
Dow JonesJan 30 17:43 ET
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsJan 27 08:31 ET · Ratings

Comments

LeMaN29

Feb 5 00:03

$Perspective Therapeutics (CATX.US)$ why?

easygoing Lyon

Jan 24 11:31

$Perspective Therapeutics (CATX.US)$ no bottom wick on 15 min. buy at 4 maybe

Jaguar8

Jan 24 08:00

NEWS

$Perspective Therapeutics (CATX.US)$
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Friday, 24th January at 7:00 am

• Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212...

Jaguar8

Jan 22 06:02

NEWS

$Perspective Therapeutics (CATX.US)$
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
Wednesday, 22nd January at 7:00 am
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated in...